Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) shares, rose in value on Wednesday, June 18, with the stock price up by 1.68% to the previous day’s close as strong demand from buyers drove the stock to $1.21.
Actively observing the price movement in the last trading, the stock closed the session at $1.19. Referring to stock’s 52-week performance, its high was $6.94, and the low was $0.72. On the whole, BCLI has fluctuated by -11.03% over the past month.
With the market capitalization of Brainstorm Cell Therapeutics, Inc currently standing at about $9.61 million, investors are eagerly awaiting this quarter’s results, scheduled for in July.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BCLI’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of BCLI currently trading nearly 4.94% and 9.34% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.91, while the 7-day volatility ratio is showing 8.39% which for the 30-day chart, stands at 4.73%. Furthermore, Brainstorm Cell Therapeutics, Inc (BCLI)’s beta value is 0.21, and its average true range (ATR) is 0.12.
A comparison of Brainstorm Cell Therapeutics, Inc (BCLI) with its peers suggests the former has fared considerably weaker in the market. BCLI showed an intraday change of 1.68% in last session, and over the past year, it shrunk by -82.84%%.
Data on historical trading for Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) indicates that the trading volumes over the past 3 months, they’ve averaged 1.28 million. According to company’s latest data on outstanding shares, there are 7.91 million shares outstanding.
Nearly 22.32% of Brainstorm Cell Therapeutics, Inc’s shares belong to company insiders and institutional investors own 12.89% of the company’s shares. The stock has fallen by -46.70% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BCLI stock heading into the next quarter.
